美国 Progenics制药公司宣称 ,他们已利用 HIV包膜蛋白研制出候选 HIV疫苗 ,该疫苗与目前正在开发的疫苗相比 ,能激发更高水平的抗体。经过数年的研究 ,他们已能够更准确地模拟天然 HIV包膜三体 ;因此 ,他们认为 ,这种模拟物可能比其他公司的疫苗更有效。动物研究已开始进行。 Progenics Pharmaceuticals of the United States has announced that it has developed a candidate HIV vaccine using HIV envelope proteins that evoke higher levels of antibodies than the vaccine currently under development. After years of research, they have been able to more accurately mimic natural HIV envelope trisomy; therefore, they believe that the mimic may be more effective than other companies’ vaccines. Animal studies have begun.